

Successful Development of Human Precision-Cut Lung Slice (hPCLS) Model for Studying Lung Disease

Laurie Perdigon, Manon Barthe, Hanan Osman-Ponchet, Agnes Choppin, Franck Chiappini

▶ To cite this version:

Laurie Perdigon, Manon Barthe, Hanan Osman-Ponchet, Agnes Choppin, Franck Chiappini. Successful Development of Human Precision-Cut Lung Slice (hPCLS) Model for Studying Lung Disease. LIVe 2024-Lung In Vitro event for innovative & predictive models, Jun 2024, Nice, France. hal-04751642

HAL Id: hal-04751642 https://hal.science/hal-04751642v1

Submitted on 24 Oct 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Successful Development of Human Precision-Cut Lung Slice (hPCLS) Model for Studying Lung Diseases



Laurie Perdigon¹, Manon Barthe¹, Hanan Osman-Ponchet¹, Agnès Choppin², Franck Chiapini²

¹ PKDERM Laboratories, Grasse Biotech, 45 Bd Marcel Pagnol, 06130 Grasse, France.



BACKGROUND


Human precision-cut lung slices (hPCLS) are emerging as a sophisticated and physiologically relevant *ex vivo* model for respiratory research. These thin, precisely-cut tissues are obtained from fresh lungs using a vibrating microtome. The hPCLS retain the native 3D architecture of the lung. This unique feature, along with the presence of all lung cell types (including smooth muscle cells, epithelial cells, and fibroblasts), makes hPCLS an ideal model for investigating lung diseases and evaluating the safety, toxicity, and efficacy of novel therapies.

This study aimed to establish a protocol for generating high-quality, viable hPCLS suitable for modeling lung diseases, especially lung fibrosis.


METHODS

Human lungs resections (Biobanque CRB, Tumorothèque de Nice, BB-0033-00025) were perfused with Hanks' Balanced Salt Solution (HBSS) to remove excess blood. The lung resection was then infused with a 2% low melting point agarose solution at 40°C. The agarose was allowed to solidify at 4°C, then a biopsy punch was used to generate a lung cores of 8 mm diameter. Lung sections of 300 µm thickness were cut using the Compresstome® VF-300-0Z (Precisionary Instruments, USA). The obtained hPCLSs were cultured in a humidified cell incubator set at 37°C and 5% CO₂ for up to 14 days.


The viability of hPCLS was investigated using MTT and Live/Dead assays. These assays evaluated the metabolic activity and membrane integrity of the hPCLS, providing insights into their overall health. ActinGreen staining further examined the structural organization of the hPCLS using fluorescence microscopy with z-stacking. Following treatment with a profibrotic cocktail¹, the functionality of hPCLS was assessed by analyzing the mRNA expression of fibrotic markers through RT-qPCR.



Infusion of lung resection with low melting agarose solution




An 8-mm punch biopsy obtained from the lung resection



Embedding of lung core on the holder




Sectionning of lung core using the Compresstome® VF-300-0Z




Human PCLS with a thickness of 300 µm


RESULTS


Live/Dead assay at Day 7 Live cells are stained in green, and dead cells are stained in red







Actin, Hematoxylin and Eosin staining indicate well-preserved lung tissue architecture in hPCLS







Treatment of hPCLS with profibrotic cocktail increases the expression of fibrotic markers



CONCLUSIONS

¹ Alsafadi et al., 2017

Despite variability in the number of hPCLS obtained from lung resections, this study demonstrates excellent viability and well-preserved architecture of hPCLS for up to 14 days in culture.

Furthermore, the obtained hPCLS exhibit increased metabolic activity over time, retain alveolar cell features, and demonstrate functional responses to stimuli, as evidenced by the expression of fibrotic markers.

We successfully established a reliable protocol for generating high-quality and functional hPCLS model.

These hPCLS can be successfully used in modeling lung diseases, particularly lung fibrosis, and screening for antifibrotic drugs.

- Bpifrance Contract N° DOS0192925/00 & DOS0192926/00, and by
- ANR-MAT-PL/ANR-22-CE18-0013

² OTR3, 4 rue Française, 75001 Paris, France.